Clinical Trials at MPTC
We are dedicated to advancing scientific knowledge about the role of proton therapy in the treatment of cancer. Clinical trials allow us to discover new and more effective treatments that would improve cancer outcomes for everyone diagnosed with the disease. With more than 30 clinical trials ongoing at our center, we are hopeful that MPTC will play a vital role in the advancement of radiation oncology.
Every patient treated at MPTC has access to a clinical trial. Read on to learn more about the trials we have available:
- NCT02603341 / GCC 15100: Pragmatic Phase III Randomized Trial of Photon vs Proton Therapy for Patients with Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial [Sponsor: U. Pennsylvania] PI: Mark V. Mishra, MD
- NCT01766297 / GCC 1570 PCG BRE007: Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer [Sponsor: PCG] PI: Elizabeth M. Nichols, MD
- EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevicuzumab in patient wih Recurrent
- NCT04181684 / GCC 19140: Pilot Study of Laser Interstitial Thermal Therapy Followed by Hypofractionated Radiation Therapy for Treatment of Recurrent Gliomas [Sponsor: U. Maryland] PI: Mark V. Mishra, MD
- NCT04699773 / GCC20138: Laser Interstitial Thermal Therapy Followed by Hypofractionated Radiation Therapy for Treatment of Newly Diagnoses High-Grade Gliomas [Sponsor: U. Maryland] PI: Mark V. Mishra, MD
- NCT03180502 / NRG BN005: Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma [Sponsor: NRG Oncology] PI: Mark V. Mishra, MD
- EA3191: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features [Sponsor: National Cancer Institute (NCI)] PI: Dan P Zandberg
- NRG HN009: Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m2) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck [Sponsor: NRG] PI: Matthew Witek, MD
- NCT03186898 / NRG GI003: A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma [Sponsor: NRG] PI: Jason Molitoris, MD, PhD
- NCT03801876 / NRG GI006: Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer [Sponsor: NRG] PI: Jason Molitoris, MD, PhD
- NCT04527900/GCC 2073: The “Upproach” Approach: A Phase 2 Study of Upfront Intensity Modulated Proton Beam Therapy (IMPT) and Concurrent Chemotherapy for Post-Operative Treatment in Loco-regionally Advanced Endometrial Cancer [Sponsor: University of Maryland] PI: Pranshu Mohindra, MD, MBBS
- GCC 2032: Phase 1 Feasibility Study of Strength Training with Androgen Deprivation and Proton Therapy for Intermediate and High Risk Prostate Cancer
- NRG GU010: Parallel Phase III Randomized Trials of Genomic-risk Stratified Unfavorable Intermiediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (Guidance)
- NCT01993810 / RTOG 1308: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC [Sponsor: RTOG] PI: Pranshu Mohindra, MD, MBBS
- NCT02745548/GCC1635: Bronchial mapping Investigating Radiation-Induced Injury to Airways and Pulmonary Vasculature in Lung Stereotactic Ablative Body Radiotherapy (SAbR) [Sponsor: U. Maryland] PI: Amit Sawant, PhD
If you’re interested in participating in a clinical trial, please call (410) 369-5351 to check on availability or speak with your physician during your consultation.
